Showing 221 - 240 results of 267 for search '"positron"', query time: 0.05s Refine Results
  1. 221

    Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics by Lorraine Gaenaelle Gé, Mathias Bogetoft Danielsen, Aaraby Yoheswaran Nielsen, Mathias Lander Skavenborg, Niels Langkjær, Helge Thisgaard, Christine J. McKenzie

    Published 2025-01-01
    “…In this context, pairing an EGFR-targeting peptide with the emerging theranostic pair comprising the Auger electron emitter cobalt-58m (<sup>58m</sup>Co) and the Positron Emission Tomography-isotope cobalt-55 (<sup>55</sup>Co) would be of great interest for creating novel radiopharmaceuticals for prostate cancer and glioblastoma theranostics. …”
    Get full text
    Article
  2. 222

    Detection of Alzheimer Disease in Neuroimages Using Vision Transformers: Systematic Review and Meta-Analysis by Vivens Mubonanyikuzo, Hongjie Yan, Temitope Emmanuel Komolafe, Liang Zhou, Tao Wu, Nizhuan Wang

    Published 2025-02-01
    “…The included papers used ViT models for AD detection versus healthy controls based on neuroimaging data, and the included studies used magnetic resonance imaging and positron emission tomography. Pooled diagnostic accuracy estimates, including sensitivity, specificity, likelihood ratios, and diagnostic odds ratios, were derived using random-effects models. …”
    Get full text
    Article
  3. 223

    AI-based automatic patient positioning in a digital-BGO PET/CT scanner: efficacy and impact by John A. Kennedy, Tala Palchan-Hazan, Zohar Keidar

    Published 2025-01-01
    “…Abstract Background A recently released digital solid-state positron emission tomography/x-ray CT (PET/CT) scanner with bismuth germanate (BGO) scintillators provides an artificial intelligence (AI) based system for automatic patient positioning. …”
    Get full text
    Article
  4. 224

    Impact of Global Mean Normalization on Regional Glucose Metabolism in the Human Brain by Kristian N. Mortensen, Albert Gjedde, Garth J. Thompson, Peter Herman, Maxime J. Parent, Douglas L. Rothman, Ron Kupers, Maurice Ptito, Johan Stender, Steven Laureys, Valentin Riedl, Michael T. Alkire, Fahmeed Hyder

    Published 2018-01-01
    “…Because the human brain consumes a disproportionate fraction of the resting body’s energy, positron emission tomography (PET) measurements of absolute glucose metabolism (CMRglc) can serve as disease biomarkers. …”
    Get full text
    Article
  5. 225

    Cerebrospinal Fluid BACE1 Activity and Brain Amyloid Load in Alzheimer's Disease by Timo Grimmer, Panagiotis Alexopoulos, Amalia Tsolakidou, Liang-Hao Guo, Gjermund Henriksen, Behrooz H. Yousefi, Hans Förstl, Christian Sorg, Alexander Kurz, Alexander Drzezga, Robert Perneczky

    Published 2012-01-01
    “…We explored associations between CSF BACE1 activity and fibrillar amyloid pathology as measured by carbon-11-labelled Pittsburgh Compound B positron emission tomography ([11C]PIB PET). [11C]PIB and CSF studies were performed in 31 patients with AD. …”
    Get full text
    Article
  6. 226

    Glucose Metabolic Brain Network Differences between Chinese Patients with Lewy Body Dementia and Healthy Control by Danyan Chen, Jiaying Lu, Hucheng Zhou, Jiehui Jiang, Ping Wu, Qihao Guo, Jingjie Ge, Huiwei Zhang, Kuangyu Shi, Chuantao Zuo

    Published 2018-01-01
    “…The technique 18F-fluorodeoxyglucose positron emission tomography (18F FDG PET) was used to investigate brain metabolism patterns in DLB patients. …”
    Get full text
    Article
  7. 227

    Rotation errors in path integration are associated with Alzheimer’s disease tau pathology: a cross-sectional study by Lise Colmant, Lisa Quenon, Lara Huyghe, Adrian Ivanoiu, Thomas Gérard, Renaud Lhommel, Pauline Coppens, Yasmine Salman, Vincent Malotaux, Laurence Dricot, Lukas Kunz, Nikolai Axmacher, Philippe Lefèvre, Bernard Hanseeuw

    Published 2025-02-01
    “…We related the path integration performance of 102 individuals without dementia, aged over 50, to amyloid and tau pathologies, measured using positron emission tomography. We included 75 clinically normal individuals (19 with brain amyloidosis, 56 without) and 27 individuals with mild cognitive impairment (18 with brain amyloidosis, 9 without). …”
    Get full text
    Article
  8. 228

    Risk Factor Analysis and Prediction of Para‐Aortic Lymph Node Metastases in Locally Advanced Cervical Cancer by Tinglu Wang, Jinchen Wei, Li Jiang, Lulu Huang, Tingting Huang, Shanshan Ma, Qiufeng Huang, Yong Zhang, Fang Wu

    Published 2024-12-01
    “…Lymph node involvement was assessed using positron emission tomography/computed tomography (PET/CT). …”
    Get full text
    Article
  9. 229
  10. 230

    Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer by Nicolas Captier, Marvin Lerousseau, Fanny Orlhac, Narinée Hovhannisyan-Baghdasarian, Marie Luporsi, Erwin Woff, Sarah Lagha, Paulette Salamoun Feghali, Christine Lonjou, Clément Beaulaton, Andrei Zinovyev, Hélène Salmon, Thomas Walter, Irène Buvat, Nicolas Girard, Emmanuel Barillot

    Published 2025-01-01
    “…We analyze baseline multimodal data from a cohort of 317 metastatic NSCLC patients treated with first-line immunotherapy, including positron emission tomography images, digitized pathological slides, bulk transcriptomic profiles, and clinical information. …”
    Get full text
    Article
  11. 231

    Mesenteric desmoid tumor after laparoscopic resection of stage I endometrial cancer: A case report by Mamiko Kusaka, Tetsuo Maeda, Kazuhiro Kitajima, Homare Murakoshi, Takahiro Watanabe, Shigeki Yoshida, Yuka Sano, Noriko Osumi, Mieko Inagaki

    Published 2025-03-01
    “…Subsequent magnetic resonance imaging and integrated positron emission tomography/CT with 2-18F-fluoro-2-deoxy-d-glucose suggested DT rather than recurrence, but surgical resection was chosen after considering the potential risks. …”
    Get full text
    Article
  12. 232

    A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review by Weizhe Han, Nihati Rexiati, Fang Yu, Yongzhi Wang, Yueli Tian, Jianyuan Wu, Gang Wang, Tao Liu, Zhonghua Yang

    Published 2025-01-01
    “…Gastrointestinal endoscopy showed no signs of gastric or colorectal cancer. Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) and prostate-specific membrane antigen PET-CT (PSMA PET-CT) indicated prostate cancer with metastases including pelvic lymph nodes, bone as well as lung metastases. …”
    Get full text
    Article
  13. 233

    A rare intersection: squamous cell carcinoma of the tonsil and the anti-TIF1 syndrome masquerade by Manush Sondhi, Megan Lear, Saleha Dar, Madiha Tariq

    Published 2025-01-01
    “…The patient underwent age-appropriate cancer screening, and due to a known association with malignancy, a positron emission scan was ordered, detecting increased activity in the right tonsil. …”
    Get full text
    Article
  14. 234

    A Novel PET Imaging Using 64Cu-Labeled Monoclonal Antibody against Mesothelin Commonly Expressed on Cancer Cells by Kazuko Kobayashi, Takanori Sasaki, Fumiaki Takenaka, Hiromasa Yakushiji, Yoshihiro Fujii, Yoshiro Kishi, Shoichi Kita, Lianhua Shen, Hiromi Kumon, Eiji Matsuura

    Published 2015-01-01
    “…Then, 11-25 mAb was labeled with 64Cu via a chelating agent DOTA and was used in both in vitro cell binding assay and in vivo positron emission tomography (PET) imaging in the tumor-bearing mice. …”
    Get full text
    Article
  15. 235

    Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adeno... by Ilham Badrane, Angelo Castello, Matteo Brunelli, Corrado Cittanti, Sara Adamantiadis, Ilaria Bagni, Noemi Mindicini, Federica Lancia, Massimo Castellani, Licia Uccelli, Mirco Bartolomei, Luca Urso

    Published 2024-12-01
    “…Prostate cancer (PCa) is a high-prevalence disease usually characterized by metastatic spread to the pelvic lymph nodes and bones and the development of visceral metastases only in the late stages of disease. Positron Emission Tomography (PET) plays a key role in the detection of PCa metastases. …”
    Get full text
    Article
  16. 236
  17. 237

    Structured reporting of neuroendocrine tumors in PET/CT using [18F]SiTATE - impact on interdisciplinary communication by Anna Hinterberger, Lukas Trupka, Sophia Kortbein, Ricarda Ebner, Nicola Fink, Matthias F. Froelich, Dominik Nörenberg, Carmen Wängler, Björn Wängler, Ralf Schirrmacher, Adrien Holzgreve, Matthias Brendel, Stefanie Corradini, Christoph Auernhammer, Johannes Rübenthaler, Freba Grawe

    Published 2025-02-01
    “…Abstract Our retrospective single-center study aims to evaluate the impact of structured reporting (SR) using a self-developed template on report quality compared to free-text reporting (FTR) in [18F]SiTATE Positron Emission Tomography/Computer Tomography (PET/CT) for the primary staging and therapy monitoring of patients diagnosed with neuroendocrine tumors (NET). …”
    Get full text
    Article
  18. 238

    Predictive Value of Initial 18F-FDG PET/CT for Identifying EGFR and KRAS Mutations in Patients with Non-small-cell Lung Cancer by Ozge Vural Topuz, Nur Buyukpinarbasili

    Published 2024-11-01
    “…Aim: Since the importance of epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog gene (KRAS) mutation status in predicting treatment response in non-small cell lung cancer (NSCLC) patients is well known, we aimed to evaluate whether initial fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET/CT) imaging could non-invasively predict EGFR or KRAS mutation states in this patient group. …”
    Get full text
    Article
  19. 239

    Synthesis and in vitro evaluation of spirobenzovesamicols as potential 11C-PET tracer alternatives to [18F]FEOBV for vesicular acetylcholine transporter (VAChT) imaging by Hugo Helbert, Winnie Deuther-Conrad, Michel de Haan, Barbara Wenzel, Gert Luurtsema, Wiktor Szymanski, Peter Brust, Rudi A. J. O. Dierckx, Ben L. Feringa, Philip H. Elsinga

    Published 2025-02-01
    “…Abstract Background Through its central role in neurotransmission, the vesicular acetylcholine transporter (VAChT) is an increasingly valuable target for positron emission tomography (PET). VAChT ligands have been mostly derived from the vesamicol structure, but with limitations in available labelling methods and selectivity for VAChT against σ receptors being a common pitfall of such compounds, the development of selective VAChT tracers remains a challenge. …”
    Get full text
    Article
  20. 240

    Pharmacokinetic Evaluation of [C]CEP-32496 in Nude Mice Bearing BRAF Mutation-Induced Melanomas by Cuiping Jiang MMSc, Lin Xie MD, PhD, Yiding Zhang BSc, Masayuki Fujinaga PhD, Wakana Mori MSc, Yusuke Kurihara PhD, Tomoteru Yamasaki PhD, Feng Wang MD, PhD, Ming-Rong Zhang MD, PhD

    Published 2018-09-01
    “…Here, we used carbon-11-labeled CEP-32496 ([ 11 C]CEP-32496) as a positron emission tomography (PET) radiotracer to evaluate its pharmacokinetic properties and explore its potential for in vivo imaging. …”
    Get full text
    Article